Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely
May 03
Hong Kong (HSI) Clinical Research and Equipment Industry Analysis
UpdatedMay 19, 2024
DataAggregated Company Financials
Companies7
- 7D-4.2%
- 3M-10.2%
- 1Y-60.3%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 4.2%, driven by declines in WuXi Biologics (Cayman) and WuXi XDC Cayman of 4.1% and 11%, respectively. Meanwhile, Viva Biotech Holdings actually outperformed within the industry, gaining 34% in the last week. Overall the industry is down 60% in 12 months. Earnings are forecast to grow by 40% annually.
Industry Valuation and Performance
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 19 May 2024 | HK$109.5b | HK$33.5b | HK$3.1b | 30.2x | 35.4x | 3.3x |
| Tue, 16 Apr 2024 | HK$108.5b | HK$33.6b | HK$3.1b | 32.8x | 35x | 3.2x |
| Thu, 14 Mar 2024 | HK$142.5b | HK$33.3b | HK$3.7b | 57.5x | 38.8x | 4.3x |
| Sat, 10 Feb 2024 | HK$125.9b | HK$32.3b | HK$3.0b | 46.7x | 42.4x | 3.9x |
| Mon, 08 Jan 2024 | HK$197.7b | HK$32.4b | HK$3.0b | 87.3x | 65.8x | 6.1x |
| Wed, 06 Dec 2023 | HK$212.4b | HK$32.4b | HK$3.0b | 78.4x | 70.7x | 6.5x |
| Fri, 03 Nov 2023 | HK$255.9b | HK$30.1b | HK$2.7b | 45x | 96x | 8.5x |
| Sun, 01 Oct 2023 | HK$245.6b | HK$30.2b | HK$2.7b | 43.6x | 91.8x | 8.1x |
| Tue, 29 Aug 2023 | HK$240.4b | HK$30.4b | HK$2.7b | 33.6x | 89.8x | 7.9x |
| Thu, 27 Jul 2023 | HK$229.6b | HK$28.5b | HK$2.7b | 24.4x | 83.5x | 8x |
| Sat, 24 Jun 2023 | HK$205.8b | HK$28.5b | HK$2.7b | 20x | 75.1x | 7.2x |
| Mon, 22 May 2023 | HK$228.3b | HK$29.0b | HK$2.8b | 22.2x | 80.4x | 7.9x |
| Wed, 19 Apr 2023 | HK$281.8b | HK$29.6b | HK$2.9b | 25.9x | 95.6x | 9.5x |
| Fri, 17 Mar 2023 | HK$257.3b | HK$26.3b | HK$2.1b | 23.8x | 125.3x | 9.8x |
| Sun, 12 Feb 2023 | HK$335.7b | HK$26.6b | HK$2.1b | 26.5x | 158.5x | 12.6x |
| Tue, 10 Jan 2023 | HK$351.2b | HK$26.5b | HK$2.1b | 27.4x | 165.1x | 13.2x |
| Thu, 08 Dec 2022 | HK$268.1b | HK$25.8b | HK$2.0b | 25.7x | 136.3x | 10.4x |
| Sat, 05 Nov 2022 | HK$237.0b | HK$25.2b | HK$1.8b | 23x | 132.8x | 9.4x |
| Mon, 03 Oct 2022 | HK$246.3b | HK$25.7b | HK$1.9b | 20.7x | 129.2x | 9.6x |
| Wed, 31 Aug 2022 | HK$361.6b | HK$25.3b | HK$2.8b | 10.6x | 131.1x | 14.3x |
| Fri, 29 Jul 2022 | HK$404.3b | HK$22.3b | HK$2.0b | 12.5x | 198.5x | 18.2x |
| Sun, 26 Jun 2022 | HK$400.1b | HK$22.5b | HK$2.1b | 16.4x | 191.6x | 17.8x |
| Tue, 24 May 2022 | HK$296.8b | HK$22.4b | HK$2.1b | 14.1x | 142.3x | 13.2x |
| Thu, 21 Apr 2022 | HK$311.8b | HK$23.2b | HK$2.3b | 14.4x | 135x | 13.4x |
| Sat, 19 Mar 2022 | HK$291.2b | HK$18.7b | HK$2.8b | 20.7x | 103.2x | 15.5x |
| Mon, 14 Feb 2022 | HK$305.1b | HK$18.7b | HK$2.8b | 25.5x | 108.6x | 16.3x |
| Wed, 12 Jan 2022 | HK$460.1b | HK$18.6b | HK$2.8b | 29.7x | 164.6x | 24.7x |
| Fri, 10 Dec 2021 | HK$563.0b | HK$18.7b | HK$2.8b | 39.2x | 200x | 30.1x |
| Sun, 07 Nov 2021 | HK$524.2b | HK$18.6b | HK$2.8b | 35.5x | 188.1x | 28.3x |
| Tue, 05 Oct 2021 | HK$586.1b | HK$18.5b | HK$2.8b | 47.8x | 212.6x | 31.8x |
| Thu, 02 Sep 2021 | HK$596.3b | HK$18.4b | HK$2.7b | 48.5x | 217.3x | 32.4x |
| Sat, 31 Jul 2021 | HK$610.8b | HK$18.4b | HK$2.7b | 53.8x | 222.6x | 33.2x |
Price to Earnings Ratio
422.9x
Current Industry PE
- Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 35.4x which is lower than its 3-year average PE of 138x.
- The 3-year average PS ratio of 15.1x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 29% per year over the last three years.
- Revenues for these companies have grown 29% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Hong Kong Clinical Research and Equipment compare with similar industries?
| HK Market | 2.56% | |
| Healthcare | -0.91% | |
| Life Sciences | -4.25% | |
| Clinical Research and Equipment | -4.25% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1873 Viva Biotech Holdings | HK$0.79 | 33.9% +HK$428.4m | -42.3% | PS0.7x | |
| 1521 Frontage Holdings | HK$1.26 | 2.4% +HK$60.7m | -42.5% | PE30.2x | |
| 6118 Austar Lifesciences | HK$0.86 | 3.6% +HK$15.4m | -54.5% | PS0.2x |